Notice of Extraordinary General Meeting in Probi AB (publ)

The shareholders of Probi AB (publ) are hereby officially convened to the Extraordinary General Meeting (EGM) which will be held on Wednesday 29 June 2016 at 10:00 a.m. at Elite Hotel Ideon, Scheelevägen 27, Lund, Sweden.

Right to participate  
To be entitled to participate in the EGM, shareholders must be registered in the shareholders’ register maintained by Euroclear Sweden AB as of Wednesday, 22 June 2016 and have notified the company of their intention to participate no later than Wednesday, 22 June 2016, preferably before 4:00 p.m.

Shareholders whose shares are registered with a trustee must temporarily re-register their shares in their own name with Euroclear Sweden AB to be able to participate in the meeting. Such registration must be completed no later than Wednesday, 22 June 2016. This means that shareholders must notify the trustee of their intention to temporarily re-register these shares in ample time before this date.

Notification of participation  
Notification of participation in the EGM is to be made by letter to the address Probi AB (publ), Ideon, Gamma 1, SE-223 70 Lund, Sweden, by e-mail to probi@probi.se or by telephone at +46 46 286 89 70. The application must include the shareholder’s name, personal identification number or corporate registration number, number of shares and, where applicable, the number of advisors (max. two) intending to participate in the meeting. If shareholders intend to be represented by proxy, a power of attorney and other authorisation documents must be included with the application. A power of attorney form is available at the company’s website www.probi.com.

Proposed agenda  

  1. Opening of the meeting
  2. Election of Chairman of the meeting
  3. Preparation and approval of the list of shareholders entitled to vote at the meeting
  4. Approval of the agenda
  5. Election of officers to verify the minutes
  6. Determination of whether the meeting has been duly convened
  7. The Board of Directors’ proposal on authorisation of the Board to resolve on a new issue of shares
  8. Closing of the meeting

The Board of Directors’ proposal on authorisation of the Board to resolve on a new issue of shares (item 7)
The Board of Directors proposes the EGM to authorise the Board to resolve on the issue of new shares with preferential right for the company’s shareholders during the period up to the company’s annual general meeting 2017. The total number of shares that may be issued by virtue of the authorisation shall amount to the number of shares corresponding to issue proceeds of approximately SEK 600,000,000, and shall be within the limits of the share capital. The purpose of the authorisation is to enable financing of the company’s acquisition of U.S probiotic company Nutraceutix’s operations. Other terms and conditions for the new share issue shall be determined by the Board.

Documentation, etc.
The Board’s proposal for authorisation will be available at the company and on its website, www.probi.se, no later than three weeks prior to the meeting and will be sent to those shareholders who so request and who state their postal address.

The number of shares of Probi AB totals 9,365,300, which carry an equal number of voting rights. Out of these shares, 250,000 shares are held by the company.

Lund in June 2016

Board of Directors of Probi AB (publ)


The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR FURTHER INFORMATION, CONTACT:

Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e-mail: peter.nahlstedt@probi.se
Niklas Brandt, CFO, Probi, tel +46 46 286 89 26 or mobile +46 706 62 98 83, e-mail: niklas.brandt@probi.se

ABOUT PROBI

Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi’s products are available to consumers in more than 30 countries worldwide. Probi’s customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. In 2015 Probi had sales of MSEK 216. The Probi share is listed on Nasdaq Stockholm, Small Cap. Probi has about 4,000 shareholders. Read more at www.probi.se .

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Contacts

Subscribe

Documents & Links